Express Pharma

Glenmark receives tentative ANDA approval for Saxagliptin

5

It is the generic version of Onglyza Tablets, 2.5 mg and 5 mg of AstraZeneca

Glenmark Pharmaceuticals has been granted tentative approval by the United States Food & Drug Administration (US FDA) for Saxagliptin Tablets, 2.5 mg and 5 mg, the generic version of Onglyza Tablets, 2.5 mg and 5 mg of AstraZeneca.

According to IMS Health sales data for the 12 month period ending April 2017, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately $518.5 million.

Comments are closed.